Amedica Corporation, a spinal and reconstructive medical device manufacturer located in Salt Lake City, Utah, has added three new executives to its leadership team and reassigned a fourth.
Amedica Significantly Beefs Up Executive Team

Vytas Rupinskas is joining Amedica as Vice President of Marketing. He brings over 25 years of marketing experience in the orthopedic, spinal and neuromodulation medical device markets and previously held senior positions at St Jude Medical, DePuy Orthopedics, DePuy International and DePuy Spine.
Joining Amedica as the new Senior Vice President of Sales is Jim Abraham. He brings over 25 years of experience in the orthopedic, trauma, spine, biologics and dental markets. Formerly with Stryker Orthopedics Abraham also previously held a number of executive positions at companies such as IsoTis Orthobiologics, Regeneration Technologies, Encore Orthopedics and Sulzermedica.
The third named is Kevin Ontiveros who joins Amedica as Chief Legal and Compliance Officer. Ontiveros has more than 20 years of experience serving as in-house and outside corporate counsel for publicly traded and privately held medical device and biotechnology/pharmaceutical companies such as ImaRx Therapeutics, Inc. and NPS Pharmaceuticals, Inc..
Paul Sendro, who was formerly Senior Vice President of Sales for Amedica, will now be leading the company’s strategic market development initiatives. He, too, has over 20 years of experience in the orthopedic, trauma and spine medical device industries, having held leadership positions at numerous companies such as US Spine, Vertebron, Blackstone Medical, Stryker Inc. and Synthes USA.

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.